Eli Lilly and Co. President and CEO-in-waiting David Ricks will inherit a well-stocked pipeline, seven drugs less than three years old and a much-improved growth trajectory. To maintain momentum, he’ll have to execute on...
Takeda said it returned its Japanese rights to fulranumab ( AMG 403 ) and trebananib ( AMG 386 ) to Amgen. In 2008, Amgen granted exclusive, Japanese rights to Takeda for up to 13 compounds,...
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it returned its Japanese rights to fulranumab ( AMG 403 ) and trebananib ( AMG 386 ) to Amgen Inc. (NASDAQ:AMGN). In April, Johnson & Johnson (NYSE:JNJ) said it...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said fasinumab ( REGN475 ) met the primary endpoint of significantly improving pain relief vs. placebo in a Phase II/III study to treat moderate to severe osteoarthritis (OA) pain of the...
The Janssen Research & Development LLC unit of Johnson & Johnson said it will discontinue its Phase III development program for osteoarthritis pain candidate fulranumab due to “strategic portfolio prioritization.” J&J, which had exclusive, worldwide...
The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) said it will discontinue its Phase III development program for fulranumab ( AMG 403 ) to treat osteoarthritis pain. J&J will return the...
FDA's Arthritis Drugs Advisory Committee voted 21-0 that anti- nerve growth factor (NGF) agents should continue to be developed to treat osteoarthritis (OA) pain. Because the joint destruction was increased in patients taking anti-NGFs with...
FDA's Arthritis Drugs Advisory Committee voted 21-0 that anti- nerve growth factor (NGF) agents should continue to be developed to treat osteoarthritis pain. Because the joint destruction was increased in patients taking anti-NGFs with NSAIDs,...
FDA will ask its Arthritis Advisory Committee on Monday whether there are any populations for which anti- nerve growth factor (NGF) pain products should be developed, given reports of joint destruction seen in clinical trials....
FDA postponed the Arthritis Advisory Committee that had been scheduled for Sept. 13 to discuss safety issues possibly related to anti- nerve growth factor (NGF) compounds. The agency said it needs time to review large...